25.36
組織移植は、失われた機能を回復することを主な目的として、ドナーからレシピエントに細胞、組織、または臓器を移植する重要な医療処置です。この処置は、腎臓病、肝不全、心臓病、特定の種類の癌など、幅広い疾患の治療に不可欠です。
組織移植の生物学
組織移植の生物学は、主要組織適合遺伝子複合体 (MHC) 分子…
組織移植は、細胞、組織、または臓器をドナーからレシピエントに移して失われた機能を回復させる、複雑でありながら重要な医療処置です。
この手順は、「自己」細胞と「非自己」細胞を区別するために不可欠なMHCまたはHLA分子の存在に大きく依存します。
これらのMHC分子は、細胞上に複数のMHCタンパク質が存在すること、MHC遺伝子多型、および各MHC遺伝子座に複数の対立遺伝子が存在するため、すべての個人に固有です。
そのため、MHC分子がレシピエントの分子と一致する適切なドナーを見つけることが主要な課題です。移植を成功させるには、少なくとも3〜4個のMHC分子が一致している必要があります。
ドナー臓器のMHC分子とレシピエントとの間の不一致は、細胞傷害性T細胞応答を引き起こし、しばしば移植拒絶反応につながる可能性があります。
多くの課題があるにもかかわらず、組織移植の治療可能性は相当なものです。たとえば、末期肝不全、心不全、または重症複合免疫不全症などの病気は、臓器移植によってうまく治療されます。
View the full transcript and gain access to JoVE Core videos
Q1: Why are MHC molecules important in tissue transplantation?
MHC molecules are essential for distinguishing 'self' and 'non-self' cells. The immune system recognizes foreign MHC molecules on transplanted tissue and can trigger a cytotoxic T cells mediated immune response, leading to transplant rejection. Each individual has a unique set of MHC molecules due to gene polymorphism and multiple alleles, making donor-recipient matching critical for transplant success.
Q2: What does MHC polymorphism mean in the context of transplantation?
MHC polymorphism refers to the presence of multiple alleles for each MHC locus, creating vast genetic variation among individuals. Combined with polygeny—the presence of multiple MHC proteins on cells—this polymorphism makes each person's MHC profile unique. This genetic diversity is why finding a suitable donor match is extremely challenging and often requires searching worldwide databases.
Q3: How many MHC molecules must match for a successful transplant?
A successful transplant typically requires a match between at least 3–4 MHC molecules between donor and recipient. More matches are associated with increased success rates and reduced risk of rejection. However, achieving even this minimum level of matching is difficult due to the extensive polymorphisms in MHC molecules across the population.
Q4: What conditions can be treated with tissue transplantation?
Tissue transplantation treats end-stage organ failure including heart, liver, and kidney failure. Bone marrow transplants successfully address Severe Combined Immunodeficiency and leukemia. However, bone marrow transplants can cause graft-versus-host disease, where transplanted cells attack recipient tissues, leading to multiple organ damage and requiring careful management.
Q5: What is graft-versus-host disease in bone marrow transplants?
Graft-versus-host disease occurs when transplanted bone marrow cells attack the recipient's own tissues, causing damage to multiple organs. This complication represents a significant challenge in bone marrow transplantation. While efforts continue to moderate its effects, it remains an important consideration when evaluating the risks and benefits of bone marrow transplants for patients.
Q6: Why is finding a donor match so difficult in tissue transplantation?
Finding a donor match is challenging because MHC molecules exhibit both polygeny and polymorphism, creating unique profiles for each individual. The extensive genetic variation in MHC loci means compatible donors are rare. Searches often extend to worldwide databases to locate unrelated donors whose MHC molecules sufficiently match the recipient's profile.
Q7: How does the immune system respond to mismatched MHC molecules?
When donor and recipient MHC molecules mismatch, the immune system recognizes the transplanted tissue as foreign. This triggers an adaptive immune response, particularly a cytotoxic T-cell response that attacks and destroys the transplanted tissue. This immune rejection is the primary barrier to successful transplantation and is why MHC matching is so critical.